Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry

• DOI: 10.3109/02770903.2012.757780
• Publication Date: 2013-01-28T05:14:35Z
• Authors: Luis Pérez de Llano; María del Carmen ...; Francisco J. Álvarez; Juan F Medina; Luis Borderías; Concha Pellicer; Héctor González; José A Gullón; Eva Martínez-Moragón; Carlos Sabadell; Soledad Zamarro; César Picado
• Keywords: Omalizumab; Allergic asthma

Aim. To evaluate the effectiveness of omalizumab in non-atopic asthma. Methods. Using data from a multicenter registry severe asthma, we evaluated and compared clinical outcome 29 omalizumab-treated asthmatics with 266 allergic asthmatics. Effectiveness was assessed by considering exacerbations, pulmonary function, Global Evaluation Treatment (GETE) scale, Asthma Control Test (ACT). Results. Omalizumab demonstrated significant improvement status as measured GETE, which rose 1.6 ± 1.1 to 2.8 0.8 at 4 months (p = .0215) 2.9 0.9 1 year .0093) 3.4 0.6 2 years .0078), ACT, increased 13.0 5.5 17.5 5.4 .0236) 17.9 4.8 .0136) 20.6 3.9 .0024). Forced expiratory volume second (FEV1) improved 61.0 19.4% 65.1 17.2 64.1 24.7 67.3 23.0 years, but without differences between initial follow-up measurements .52, .91, .45, respectively) exacerbations decreased 3.1 3.5 1.9 .1709) 1.8 4.4 .2344). The results were not significantly different those obtained atopic Conclusion. Anti-IgE therapy can be effective